Tissue microarray analyzed that HER2, EGFR, MET and FGFR2 predominances were respectively observed in 10.1, 13.9, 16.1 and 22.9% of the gastric adenocarcinomas. This evidence concerns the gene FGFR2 and gastric adenocarcinoma.